You have free access to this content

British Journal of Clinical Pharmacology

Cover image for Vol. 61 Issue 3

March 2006

Volume 61, Issue 3

Pages 243–363

  1. Editors' view

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Rare diseases and orphan drugs (pages 243–245)

      J. K. Aronson

      Version of Record online: 16 FEB 2006 | DOI: 10.1111/j.1365-2125.2006.02617.x

  2. Review

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
  3. Pharmacodynamics

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans (pages 256–261)

      Eri Takizawa, Daisuke Takizawa, Haruhiko Hiraoka, Shigeru Saito and Fumio Goto

      Version of Record online: 13 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02555.x

      • image
      • image
    2. You have free access to this content
      Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy (pages 262–274)

      Ulrike Resch, Franz Tatzber, Alexandra Budinsky and Helmut Sinzinger

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02568.x

  4. Pharmacokinetics

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males (pages 275–279)

      Z. Chik, A. Johnston, A. T. Tucker, S. L. Chew, L. Michaels and C. A. S. Alam

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02542.x

      • image
      • image
    2. You have free access to this content
      Tadalafil pharmacokinetics in healthy subjects (pages 280–288)

      S. Thomas Forgue, Beverley E. Patterson, Alun W. Bedding, Christopher D. Payne, Diane L. Phillips, Rebecca E. Wrishko and Malcolm I. Mitchell

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02553.x

      • image
      • image
      • image
  5. Pharmacokinetics & pharmacodynamics

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone (pages 289–300)

      Julie A. Simpson, Dyfrig Hughes, Christine Manyando, Kalifa Bojang, Leon Aarons, Peter Winstanley, Geoffrey Edwards, William A. Watkins and Steve Ward

      Version of Record online: 10 JAN 2006 | DOI: 10.1111/j.1365-2125.2005.02567.x

      • image
      • image
      • image
      • image
      • image
      • image
  6. Pharmacogenetics

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
    2. You have free access to this content
      Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status (pages 309–314)

      Tsukasa Uno, Mikiko Shimizu, Norio Yasui-Furukori, Kazunobu Sugawara and Tomonori Tateishi

      Version of Record online: 1 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02556.x

      • image
    3. You have free access to this content
      Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes (pages 315–320)

      Masatomo Miura, Hideaki Kagaya, Hitoshi Tada, Tsukasa Uno, Norio Yasui-Furukori, Tomonori Tateishi and Toshio Suzuki

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02566.x

      • image
    4. You have free access to this content
      The influence of CYP2D6 genotype on trough plasma perhexiline and cis-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia (pages 321–325)

      Benjamin J. Davies, Janet K. Coller, Heather M. James, Andrew A. Somogyi, John D. Horowitz and Benedetta C. Sallustio

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02570.x

      • image
  7. Drug metabolism

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
  8. Therapeutics

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection (pages 336–340)

      T. Todros, P. Verdiglione, G. Oggè, D. Paladini, P. Vergani and S. Cardaropoli

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02572.x

  9. Prescribing

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
  10. Education

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Curriculum development in pharmacotherapy: testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial (pages 345–351)

      J. A. Vollebregt, J. C. M. Metz, M. De Haan, M. C. Richir, J. G. Hugtenburg and T. P. G. M. De Vries

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02571.x

      • image
  11. Short reports

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Initial phase of chronic medication use; patients’ reasons for discontinuation (pages 352–354)

      J. G. Hugtenburg, A. Th. G. Blom and S. U. Kisoensingh

      Version of Record online: 20 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02569.x

    2. You have free access to this content
      Orphan drug development is progressing too slowly (pages 355–360)

      Roberta Joppi, Vittorio Bertele and Silvio Garattini

      Version of Record online: 20 JAN 2006 | DOI: 10.1111/j.1365-2125.2006.02579.x

  12. Letters to the editors

    1. Top of page
    2. Editors' view
    3. Review
    4. Pharmacodynamics
    5. Pharmacokinetics
    6. Pharmacokinetics & pharmacodynamics
    7. Pharmacogenetics
    8. Drug metabolism
    9. Therapeutics
    10. Prescribing
    11. Education
    12. Short reports
    13. Letters to the editors
    1. You have free access to this content
      Hydroxylation of lansoprazole in poor metabolizers of CYP2C19 (page 361)

      Takahisa Furuta, Naohito Shirai, Mitsushige Sugimoto, Akiko Nakamura and Akira Hishida

      Version of Record online: 1 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02551.x

    2. You have free access to this content
      Author's reply: Hydroxylation of lansoprazole in poor metabolizers of CYP2C19 (pages 361–362)

      Norio Yasui-Furukori, Tsukasa Uno, Sunao Kaneko and Tomonori Tateishi

      Version of Record online: 1 DEC 2005 | DOI: 10.1111/j.1365-2125.2005.02552.x

    3. You have free access to this content
      ASCOT – old or new drugs for blood pressure? (page 363)

      James Ritter and John Warren

      Version of Record online: 4 JAN 2006 | DOI: 10.1111/j.1365-2125.2006.02564.x

SEARCH

SEARCH BY CITATION